查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612741

Canavan 疾病治疗药物市场：治疗方法、最终用户、分销管道 - 全球预测 2025-2030

Canavan Disease Therapeutics Market by Treatment (Gene therapy, Medication, Supportive Treatments), End-user (Homecare, Hospitals, Specialty clinics), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年卡纳万疾病治疗市值为5.2729亿美元，预计到2024年将达到5.5666亿美元，复合年增长率为5.88%，预计到2030年将达到7.871亿美元。

卡纳万病是一种罕见的遗传性神经系统疾病，主要影响儿童，其特征是大脑白质变性。该领域的治疗方法包括开发可以解决潜在遗传和生化原因的标靶治疗。由于这种疾病使人衰弱，并且没有明确的治疗方法，因此非常需要有效的药物来治疗卡纳万病。目前的应用重点是透过基因治疗、酵素替代和支持性护理来改善生活品质和缓解症状。最终用途范围主要集中在儿科神经科、专科诊所和专门研究罕见遗传疾病的研究机构。

主要市场统计
基准年[2023] 5.2729亿美元
预测年份 [2024] 55666万美元
预测年份 [2030] 7.871 亿美元
复合年增长率（%） 5.88%

市场洞察表明，基因治疗和精准医学的进步是卡纳万病药物成长的关键驱动力。研究经费的增加、对罕见疾病的认识不断提高以及基因组医学的进步为市场扩张提供了重大机会。投资于获得孤儿药指定的创新治疗方法的生物技术公司将获得大量资本。然而，高昂的研发成本、严格的监管要求和有限的患者人数等挑战可能会阻碍市场成长。作为一种罕见疾病，临床试验招募和资料收集非常复杂，使得治疗方法开发变得更加困难。

扩大对 CRISPR 等基因编辑技术的研究可以提供更精确的干预措施。开发公司还可以探索与学术研究机构的合作，以加速治疗开发和临床试验过程。为了克服市场限制，与患者倡导组织建立伙伴关係可以提高意识并鼓励患者参与临床试验。创新可以集中于开发用于早期诊断的生物标记、优化基因治疗的传递载体以及加强支持性护理。由于市场的性质，专注于罕见疾病领域的参与者有限且高度专业化，因此公司优先考虑稳固的研发和策略联盟非常重要。

市场动态：快速发展的卡纳万病药物市场揭示的关键市场洞察

卡纳万病药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 卡纳万病患病率增加
    • 改进诊断技术并提高全球对卡纳万病的认识
  • 市场限制因素
    • 治疗成本高且商业化有限
  • 市场机会
    • 基因治疗技术取得重大进展
    • 研究机构与製药公司的策略联盟
  • 市场挑战
    • 卡纳万病药物开发的监管和标准化挑战

波特五力：驾驭卡纳万病药物市场的策略工具

波特的五力架构是了解卡纳万疾病治疗药物市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解卡纳万病药物市场的外部影响

外部宏观环境因素在塑造 Canavan 疾病治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 Canavan 疾病治疗药物市场的竞争状况

对 Canavan 疾病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

Canavan 疾病治疗药物市场中的 FPNV 定位矩阵供应商绩效评估

FPNV 定位矩阵是评估 Canavan 疾病治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为 Canavan 疾病治疗药物市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对 Canavan 疾病治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 卡纳万病患病率增加
      • 改进诊断技术并提高全球对卡纳万病的认识
    • 抑制因素
      • 治疗成本高且商业化受到限制
    • 机会
      • 基因治疗技术的重大进展
      • 研究机构与製药公司的策略合作
    • 任务
      • 卡纳万病药物开发的监管和标准化挑战
  • 市场区隔分析
    • 治疗：基因疗法在卡纳万病治疗的新应用
    • 最终用户：医院更多采用卡纳万病药物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 Canavan 疾病治疗药物市场（依治疗）

  • 基因治疗
  • 药物治疗
  • 支持性护理

第七章 Canavan 疾病治疗药物市场：依最终使用者分类

  • 居家护理
  • 医院
  • 专科诊所

第八章 Canavan 疾病治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章 美洲卡纳万病药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区Canavan疾病治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲卡纳万病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Myrtelle Inc. 的 rAAV-Olig001-ASPA 已获得美国食品药物管理局(FDA)核准。
    • NADER计划：Burjeel Holdings 和 BridgeBio Pharma, Inc. 发起的罕见疾病早期诊断和治疗计画。
    • BridgeBio Pharma, Inc. 与 National Resilience, Inc. 结成策略联盟，加强罕见疾病基因治疗药物的生产
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc.
  • Amgen, Inc.
  • Anjarium Biosciences AG
  • Astellas Pharma Inc.
  • Biogen Inc.
  • BridgeBio Pharma
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Myrtelle, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Orphan Star Therapeutics LLC
  • Pfizer, Inc.
  • Sanofi SA
  • Sio Gene Therapies Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Voyager Therapeutics, Inc.
Product Code: MRR-99555D550525

The Canavan Disease Therapeutics Market was valued at USD 527.29 million in 2023, expected to reach USD 556.66 million in 2024, and is projected to grow at a CAGR of 5.88%, to USD 787.10 million by 2030.

Canavan Disease is a rare, genetic neurological disorder that primarily affects children, characterized by the degeneration of white matter in the brain. The scope of therapeutics in this area involves the development of targeted treatments that can address the underlying genetic and biochemical causes. The necessity for effective Canavan Disease therapeutics is high due to its debilitating nature and lack of a definitive cure. Current applications focus on improving quality of life and alleviating symptoms through gene therapy, enzyme replacement, and supportive care. The end-use scope is primarily concentrated in pediatric neurology departments, specialty clinics, and research institutions dedicated to rare genetic disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 527.29 million
Estimated Year [2024] USD 556.66 million
Forecast Year [2030] USD 787.10 million
CAGR (%) 5.88%

Market insights reveal that advancements in gene therapy and precision medicine are key driving factors for growth in Canavan Disease therapeutics. Increased research funding, greater awareness of rare diseases, and advancements in genomic medicine are providing significant opportunities for market expansion. Biotech companies investing in innovative treatment modalities with orphan drug designations stand to capitalize significantly. However, challenges such as high R&D costs, stringent regulatory requirements, and the limited patient population can impede market growth. The rarity of the disease complicates clinical trial recruitment and data collection, further challenging therapeutic development.

Opportunities lie in expanding research on gene-editing technologies like CRISPR, which could offer more precise interventions. Companies can also explore collaborations with academic research institutions to expedite therapeutic development and clinical trial processes. To overcome market limitations, fostering partnerships with patient advocacy groups can enhance awareness and patient enrollment in trials. Innovation could focus on developing biomarkers for early diagnosis, optimizing delivery vectors for gene therapy, and enhancing supportive care regimes. The nature of the market is highly specialized, with a limited number of players focusing on niche rare disease segments, making it crucial for companies to prioritize robust research development and strategic collaborations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Canavan Disease Therapeutics Market

The Canavan Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of canavan disease
    • Enhanced diagnostic techniques and increased global awareness about canavan disease
  • Market Restraints
    • High cost of treatment coupled with limited commercialization
  • Market Opportunities
    • Significant advancements in gene therapy techniques
    • Strategic collaborations between research institutes and pharmaceutical companies
  • Market Challenges
    • Regulatory and standardization challenges in canavan disease therapeutics development

Porter's Five Forces: A Strategic Tool for Navigating the Canavan Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Canavan Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Canavan Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Canavan Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Canavan Disease Therapeutics Market

A detailed market share analysis in the Canavan Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Canavan Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Canavan Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Canavan Disease Therapeutics Market

A strategic analysis of the Canavan Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Canavan Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Amgen, Inc., Anjarium Biosciences AG, Astellas Pharma Inc., Biogen Inc., BridgeBio Pharma, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Myrtelle, Inc., Novartis AG, Orchard Therapeutics PLC, Orphan Star Therapeutics LLC, Pfizer, Inc., Sanofi SA, Sio Gene Therapies Inc., Ultragenyx Pharmaceutical Inc., and Voyager Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Canavan Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Gene therapy, Medication, and Supportive Treatments.
  • Based on End-user, market is studied across Homecare, Hospitals, and Specialty clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of canavan disease
      • 5.1.1.2. Enhanced diagnostic techniques and increased global awareness about canavan disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment coupled with limited commercialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant advancements in gene therapy techniques
      • 5.1.3.2. Strategic collaborations between research institutes and pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and standardization challenges in canavan disease therapeutics development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Emerging application of gene therapy to treat Canavan disease
    • 5.2.2. End-user: Increasing adoption of Canavan disease therapeutics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Canavan Disease Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Gene therapy
  • 6.3. Medication
  • 6.4. Supportive Treatments

7. Canavan Disease Therapeutics Market, by End-user

  • 7.1. Introduction
  • 7.2. Homecare
  • 7.3. Hospitals
  • 7.4. Specialty clinics

8. Canavan Disease Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Canavan Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Canavan Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Canavan Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Myrtelle Inc. received approval from the U.S. Food and Drug Administration (FDA) for rAAV-Olig001-ASPA
    • 12.3.2. Project NADER: An Initiative for Early Diagnosis and Treatment of Rare Diseases by Burjeel Holdings and BridgeBio Pharma, Inc.
    • 12.3.3. Strategic Collaboration between BridgeBio Pharma, Inc. and National Resilience, Inc. to Boost Gene Therapy Manufacturing for Rare Diseases
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Amgen, Inc.
  • 3. Anjarium Biosciences AG
  • 4. Astellas Pharma Inc.
  • 5. Biogen Inc.
  • 6. BridgeBio Pharma
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. GlaxoSmithKline PLC
  • 9. Johnson & Johnson Services, Inc.
  • 10. Myrtelle, Inc.
  • 11. Novartis AG
  • 12. Orchard Therapeutics PLC
  • 13. Orphan Star Therapeutics LLC
  • 14. Pfizer, Inc.
  • 15. Sanofi SA
  • 16. Sio Gene Therapies Inc.
  • 17. Ultragenyx Pharmaceutical Inc.
  • 18. Voyager Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. CANAVAN DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANAVAN DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANAVAN DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUPPORTIVE TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023